John M Erikson, MD

Private

Funding Agency Evalve, Inc. Title EVEREST II - A study of the Evalve Cardiovascular Valve Repair System (CVRS). Status Active Period 12/2004 - Present Role Co-Investigator Grant Detail   Funding Agency Edwards Lifesciences Corp Title The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII A (PARTNERII A) Status Active Period 9/2012 - 1/2029 Role Contributor Grant Detail The safety and effectiveness of the SAPIEN XT transcatheter heart valve with novaflex ASCENDRA/ASCENDRA II Delivery systems in intermediate risk for aortic valve surgery and patients who cannot undergo surgery Funding Agency Texas Alzheimer`s Research and Care Consortium Title Texas Alzheimer`s Research and Care Consortium Status Active Period 8/2018 - 8/2020 Role Contributor Grant Detail In summary, with this proposal we seek to utilize the cohort assembled by the TARCC in conjunction with participating clinics at UTHSCSA to help clarify the relationship between diastolic dysfunction and cognition. Repeated brain MRI will study structural change over time, and will include the novel analysis of the Alzheimer?s cortical signature7. Comprehensive neuropsychological testing will elucidate the pattern of cognitive impairment associated with diastolic dysfunction, which can help determine the extent of change in brain function. Results from this project will be of assistance in the development of new avenues of research for the prevention, treatment and management of dementia. The incidence rate of development of dementia would be significantly lowered by the correction of a widespread risk factor. At present, diastolic dysfunction is medically managed only when cardiac symptoms such as exercise intolerance or volume overload are present, as no therapy has been shown to improve the outcomes of all-cause or cardiovascular mortality and hospitalizations for heart failure11. If diastolic dysfunction is found to be associated with the development of cognitive impairment, increased emphasis on the treatment of diastolic dysfunction should be considered, such as with the use of rate-slowing agents, restoration of normal sinus rhythm, relieving volume overload, decreasing venous pressure, and controlling hypertension12. Funding Agency Eisai Pharmaceuticals Title Eisai APD356-A001-403. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR? in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years. Status Active Period 10/2017 - 12/2019 Role Contributor Grant Detail   Funding Agency Eisai Pharmceuticals Title Eisai APD356-G000-401. CAMELLIA-TIMI 61 (Cardiovascular And Metabolic Effects of Lorcaserin In Overweight And Obese Patients) Status Complete Period 10/2014 - 10/2017 Role Contributor Grant Detail Eisai APD356-G000-401. CAMELLIA-TIMI 61 (Cardiovascular And Metabolic Effects of Lorcaserin In Overweight And Obese Patients) is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors.